Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Shareholders of Novoship approved dividends for 2023

7/2/24 NOMP

RusHydro awaits the decision of its major shareholder

7/1/24 HYDR

RusHydro shareholders failed to approve dividends for 2023 results

7/1/24 HYDR

Shareholders of Moscow confectionery factory Krasny Oktyabr approved dividends for 2023

7/1/24 KROT

Cosmos Hotel Group will increase its room stock 4.8 times

7/1/24 AFKS

Russneft withdraws from assets in Azerbaijan

7/1/24 RNFT

Shareholders of Udmurtneft approved dividends for 2023

7/1/24 UDMN

Shareholders of Novorossiysk Bakery Products Plant approved dividends for 2023

7/1/24 NKHP

Lenta brought fresh to Ozon

7/1/24 LENT

Alrosa acquired a gold deposit

7/1/24 ALRS